CoChat

Role of Bupropion Plus Naltrexone for the Management of Obesity

Open access
Booth, Kemper, Clements, Jennifer N. · 2016 · Journal of Pharmacy Technology

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Objective. The pharmacology, pharmacokinetics, efficacy, and safety of bupropion plus naltrexone for weight loss were reviewed. Data Sources. A MEDLINE search (1970 to November 2015) was conducted for English-language articles using specific MESH terms. Study Selection and Data Extraction. Published Phase 3 clinical trials with primary endpoints related to weight loss were included and critiqued in this review. Study Selection and Data Extraction. Five trials were retrieved and reviewed regarding the efficacy and safety of bupropion plus naltrexone among obese and overweight patients. Data Synthesis. Bupropion is a dopamine/norepinephrine reuptake inhibitor, and naltrexone is an opioid receptor antagonist. The combination of these agents has led to increased weight loss, compared to placebo, among overweight and obese patients with a body mass index (BMI) at or above 30 or BMI at or above 27 with a comorbid condition. The combination of bupropion and naltrexone can produce an average placebo-subtracted weight loss of 4.25% over 56 weeks. Gastrointestinal (ie, nausea, vomiting, constipation) and central nervous system adverse events (ie, headache, dizziness) were commonly reported, and there was a high dropout rate among participants. Conclusions. Bupropion plus naltrexone has demonstrated effective weight loss, in conjunction with lifestyle modifications, among overweight and obese patients with and without comorbidities. Bupropion plus naltrexone has not been studied among special patient populations, such as those with sleep apnea, osteoarthritis, or extreme BMIs. Additional clinical trials and postmarketing data will provide a better understanding of this medication for weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/8755122515624220

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 5

  1. 8. Contrave [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc, and La Jolla, CA: Orexigen Therapeutics, Inc; 2014. [Google Scholar]
  2. 13. Wellbutrin [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014. [Google Scholar]
  3. 14. Zyban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015. [Google Scholar]
  4. 19. Naltrexone [package insert]. Sellersville, PA: Teva Pharmaceuticals, Inc; 2013. [Google Scholar]
  5. 32. O’Riordan M. LIGHT stopped: Contrave CVD safety study halted following premature release of data. Medscape News Alerts. http://www.medscape.com/viewarticle/844575. Published May 12, 2015. Accessed December 17, 2015. Articles from The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians are provided here courtesy of SAGE Publications

Cited by

See all 13

Metadata

Authors
Booth, K., & Clements, J. N.
Affiliations
Presbyterian College (US)
Corresponding author
Clements, Jennifer N.
Venue
Journal of Pharmacy Technology
Published
2016-01-11
Volume
32
Issue
3
Pages
125-132
ISSN
  • 1549-4810 (ISSN-L)
  • 8755-1225
OpenAlex
W2341654874
Cited by
13
References
22
Citations by year
2026: 1 · 2025: 5 · 2024: 3 · 2023: 3 · 2017: 1
FWCI
0.27
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Pharmacy Technology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
bupropion, naltrexone, combination pharmacotherapy, obesity, weight loss, opioid antagonists, pharmacokinetics, gastrointestinal adverse effects, central nervous system adverse events, lifestyle modification, overweight, comorbid obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Bupropion Plus Naltrexone for the Management of Obesity. https://app.cochat.ai/papers/10.1177/8755122515624220
The paper
Booth, K., & Clements, J. N. (2016). Role of Bupropion Plus Naltrexone for the Management of Obesity. Journal of Pharmacy Technology. https://doi.org/10.1177/8755122515624220

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.